STAT June 21, 2024
Elizabeth Cooney

ORLANDO — The United States is at a critical juncture in its efforts to treat chronic diseases, particularly type 2 diabetes, and now has a chance to change the dangerous trajectory it’s currently following, FDA Commissioner Robert Califf said Friday.

“The U.S. is leading the world in technology development, innovation, new gadgets of all kinds, new drugs, you name it,” he said. “These advantages unfortunately are not resulting in superior health and outcomes for the U.S., population, or for most individuals in the U.S.”

Health outcomes as a whole are deteriorating in the U.S., Califf said in his remarks at the American Diabetes Association conference, but he sees one outlier.

“There’s an exception for type 1 diabetes, which I believe...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Digital Health, FDA, Govt Agencies, Patient / Consumer, Provider, Technology, Wearables
Related Articles:
What A Potential FDA Red Dye No. 3 Ban Could Mean For Public Health
STAT+: Former Trump FDA, CMS heads lay out how his return could reshape health policy
The Overdue Imperative Of Cross-Racial Pulse Oximeters
FDA’s evolving regulatory framework for AI use in drug & device clinical trials and research
FDA has approved over 1,000 clinical AI applications, with most aimed at radiology

Share This Article